Carlyle’s Abingworth will help fund Teva’s Phase 3 asthma rescue inhaler

Abingworth will provide up to $150 million to help fund Teva Pharmaceuticals’ development of an asthma rescue inhaler, the companies said Monday morning.

The asset, known as ICS-SABA/TEV-’248, entered Phase 3 testing last fall and will have results in the second half of 2026, according to a Teva presentation from January.

The inhaler could work for adults and children, Teva has said. It combines the “two most widely used molecules,” which are fluticasone propionate and albuterol sulfate. The Israel-based pharma in January touted a $2.5 billion potential market.

If the multi-dose, dry powder inhaler secures FDA approval, Teva would make fixed payments to Abingworth as well as payments based on sales, the companies said. Teva retains the full rights and will be in the driver’s seat for manufacturing, US regulatory interactions and commercialization, they said.

Anshul Thakral


Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks